Michael Y.T. Chow

Dr. Michael Y.T. Chow

School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2022 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
Rachel Yoon ChangRachel Yoon Chang
Rachel Yoon Chang
MLMengyu Li
Mengyu Li
MCMichael Y.T. Chow
Michael Y.T. Chow
WKWei-Ren Ke
Wei-Ren Ke
WTWaiting Tai
Waiting Tai
HCHak-Kim Chan
Hak-Kim Chan

30 November 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
ZSZitong Shao
Zitong Shao
WTWaiting Tai
Waiting Tai
YQYingshan Qiu
Yingshan Qiu
RMRico C. H. Man
Rico C. H. Man
QLQiuying Liao
Qiuying Liao
JLJenny K. W. Lam
Jenny K. W. Lam
Multi-drug-resistant tuberculosis (MDR-TB) is a huge public health problem. The treatment regimen of MDR-TB requires prolonged chemotherapy with multiple drugs including second-line anti-TB agents associated with severe adverse effects. Capreomycin, a polypeptide antibiotic, is the first choice of second-line anti-TB drugs in MDR-TB therapy. It requires repeated intramuscular or intravenous administration five times per week. Pulmonary drug delivery is non-invasive with the advantages of local targeting and reduced risk of systemic toxicity. In this study, inhaled dry powder formulation of capreomycin targeting the lung was developed using spray drying technique. Among the 16 formulations designed, the one containing 25% capreomycin (w/w) and spray-dried at an inlet temperature of 90 °C showed the best overall performance with the mass median aerodynamic diameter (MMAD) of 3.38 μm and a fine particle fraction (FPF) of around 65%. In the pharmacokinetic study in mice, drug concentration in the lungs was approximately 8-fold higher than the minimum inhibitory concentration (MIC) (1.25 to 2.5 µg/mL) for at least 24 h following intratracheal administration (20 mg/kg). Compared to intravenous injection, inhaled capreomycin showed significantly higher area under the curve, slower clearance and longer mean residence time in both the lungs and plasma.

14 August 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
WTWaiting Tai
Waiting Tai
MCMichael Y.T. Chow
Michael Y.T. Chow
Rachel Yoon ChangRachel Yoon Chang
Rachel Yoon Chang
PTPatricia Tang
Patricia Tang
IGIgor Gonda
Igor Gonda
Philip Chi Lip KwokPhilip Chi Lip Kwok
Philip Chi Lip Kwok
The coronavirus disease 2019 (COVID-19) is an unprecedented pandemic that has severely impacted global public health and the economy. Hydroxychloroquine administered orally to COVID-19 patients was ineffective, but its antiviral and anti-inflammatory actions were observed in vitro. The lack of efficacy in vivo could be due to the inefficiency of the oral route in attaining high drug concentration in the lungs. Delivering hydroxychloroquine by inhalation may be a promising alternative for direct targeting with minimal systemic exposure. This paper reports on the characterisation of isotonic, pH-neutral hydroxychloroquine sulphate (HCQS) solutions for nebulisation for COVID-19. They can be prepared, sterilised, and nebulised for testing as an investigational new drug for treating this infection. The 20, 50, and 100 mg/mL HCQS solutions were stable for at least 15 days without refrigeration when stored in darkness. They were atomised from Aerogen Solo Ultra vibrating mesh nebulisers (1 mL of each of the three concentrations and, in addition, 1.5 mL of 100 mg/mL) to form droplets having a median volumetric diameter of 4.3–5.2 µm, with about 50–60% of the aerosol by volume < 5 µm. The aerosol droplet size decreased (from 4.95 to 4.34 µm) with increasing drug concentration (from 20 to 100 mg/mL). As the drug concentration and liquid volume increased, the nebulisation duration increased from 3 to 11 min. The emitted doses ranged from 9.1 to 75.9 mg, depending on the concentration and volume nebulised. The HCQS solutions appear suitable for preclinical and clinical studies for potential COVID-19 treatment.

15 July 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
MCMichael Y.T. Chow
Michael Y.T. Chow
Rachel Yoon ChangRachel Yoon Chang
Rachel Yoon Chang
MLMengyu Li
Mengyu Li
YWYuncheng Wang
Yuncheng Wang
YLYu Lin
Yu Lin
HCHak-Kim Chan
Hak-Kim Chan
Inhaled bacteriophage (phage) therapy is a potential alternative to conventional antibiotic therapy to combat multidrug-resistant (MDR) Pseudomonas aeruginosa infections. However, pharmacokinetics (PK) and pharmacodynamics (PD) of phages are fundamentally different to antibiotics and the lack of understanding potentially limits optimal dosing. The aim of this study was to investigate the in vivo PK and PD profiles of antipseudomonal phage PEV31 delivered by pulmonary route in mice. BALB/c mice were administered phage PEV31 at doses of 10 7 and 10 9 PFU by the intratracheal route. Mice ( n = 4) were sacrificed at 0, 1, 2, 4, 8 and 24 h post-treatment and various tissues (lungs, kidney, spleen and liver), bronchoalveolar lavage and blood were collected for phage quantification. In a separate study, mice ( n = 4) were treated with PEV31 (10 9 PFU) or PBS at 2 h post-inoculation with MDR P. aeruginosa . Infective PEV31 and bacteria were enumerated from the lungs. In the phage only study, PEV31 titer gradually decreased in the lungs over 24 hours with a half-life of approximately 8 h for both doses. In the presence of bacteria, PEV31 titer increased by almost 2-log 10 in the lungs at 16 h. Furthermore, bacterial growth was suppressed in the PEV31-treated group, while the PBS-treated group showed exponential growth. Some phage-resistant colonies were observed from the lung homogenates sampled at 24 h post-phage treatment. These colonies had a different antibiogram to the parent bacteria. This study provides evidence that pulmonary delivery of phage PEV31 in mice can reduce the MDR bacterial burden.